29 Amendments of Cristian-Silviu BUŞOI related to 2014/2207(INI)
Amendment 5 #
Motion for a resolution
Citation 11 a (new)
Citation 11 a (new)
- having regard to the Latvian Presidency efforts in addressing antimicrobial resistance, in particular with regards to Tuberculosis and Multi-Drug Resistant Tuberculosis;
Amendment 47 #
Motion for a resolution
Recital M a (new)
Recital M a (new)
Ma. whereas vaccination is an effective way to reduce the threat of antibacterial resistance by preventing infections that would need treatment with antibacterials and thereby reducing development of resistance;
Amendment 64 #
Motion for a resolution
Recital O
Recital O
O. whereas resistance to antibiotics for certain bacteria is at least 25 % or more in several Member States; whereas antibiotic resistance is spreading much faster than the introduction of new antibiotics into clinical practice and that this is linked to scientific, regulatory and economic challenges;
Amendment 65 #
Motion for a resolution
Recital O a (new)
Recital O a (new)
Oa. whereas antibacterial research and development presents some unique challenges meaning that a long term perspective is needed to develop the expertise and apply it in laboratories and whereas it is regrettable that many researchers with such an expertise have moved in other areas due to a lack of both private and public funding;
Amendment 70 #
Motion for a resolution
Recital P a (new)
Recital P a (new)
Pa. whereas increasing scientific evidence shows that good hand hygiene in healthcare settings requires the use of methods to dry hands that do not facilitate microbial cross-contamination via airborne dissemination and aerosolization;
Amendment 71 #
Motion for a resolution
Recital P a (new)
Recital P a (new)
Pa. whereas, pharmaceutical companies tend to add new antibiotics within existing classes of antibiotics rather than discover and develop truly new antibacterial agent; as a result, resistance to these new agents will emerge faster than for drugs with a truly new mechanism of action;
Amendment 77 #
Motion for a resolution
Recital Q
Recital Q
Q. whereas it is of paramount importance to encourage pharmaceutical companies to continue investing and to invest in developing new antibiotic compounds, in particular with activity against prevalent multidrug-resistant Gram-negative bacteria such as K. pneumoniae and Acinetobacterthose diseases for which antimicrobial resistance is a serious concern such as K. pneumonia, E. Coli, Acinetobacter, staphylococcus aureus, HIV, Tuberculosis and Malaria, by creating a new market model to incentivise investment in research and development and focus it on highest public health needs;
Amendment 92 #
Motion for a resolution
Recital R a (new)
Recital R a (new)
whereas the internet is the largest unregulated pharmaceutical market in the world and illicit online pharmacies contribute to the increasing risk of counterfeit medicines; whereas there is still a growing percent of medicines purchased from illicit internet websites, some of them from so called non- regulated outlets due to their cheaper prices and financial constraints of the patients; whereas patients raise concerns over the authenticity and safety of medicines available over the internet;
Amendment 97 #
Motion for a resolution
Recital S a (new)
Recital S a (new)
Sa. whereas patients, families and patient organisations play a key role in advocating for safer care, and their role should be promoted through patient empowerment and participation in the healthcare process and policy at all levels;
Amendment 149 #
Motion for a resolution
Paragraph 7 a (new)
Paragraph 7 a (new)
7a. Calls the European Commission and Member States to assess the potential of mobile health (mhealth) on care efficiency, hospitalisation's incidence and on the annual per capita healthcare cost reduction;
Amendment 158 #
Motion for a resolution
Paragraph 9 a (new)
Paragraph 9 a (new)
9a. Calls on the European Commission and the European Centre for Disease Prevention and Control to develop guidelines for healthcare professionals, patients and their families on effective hand washing and drying and encouraging the use of hand drying methods that do not facilitate microbial cross-contamination via airborne dissemination and aerosolization;
Amendment 162 #
Motion for a resolution
Paragraph 9 b (new)
Paragraph 9 b (new)
9b. Calls on the European Commission and Member States to develop EU guidance for patients' involvement in patient safety strategies and actions in collaboration with stakeholders, particularly patient organisations;
Amendment 163 #
Motion for a resolution
Paragraph 9 c (new)
Paragraph 9 c (new)
9c. Calls on the European Commission and Member States to develop EU Guidance on the provision of information to patients on patient safety in collaboration with stakeholders, particularly patient organisations;
Amendment 189 #
Motion for a resolution
Paragraph 17
Paragraph 17
17. Notes with concern that between 2010 and 2013 the percentages of K. pneumoniae resistant to fluoroquinolones, third-generation cephalosporins and aminoglycosides, as well as combined resistance to all three antibiotic groups, significantly increased in many Member States and at EU level; further notes that during the same period resistance to third- generation cephalosporins also significantly increased in many Member States and at EU level for E. coli, further notes that in certain regions of Europe multi-drug resistant tuberculosis makes up to 20 per cent of all new tuberculosis cases and treatment outcomes for MDR- TB are alarmingly low;
Amendment 193 #
Motion for a resolution
Paragraph 18
Paragraph 18
18. Regrets that the past 25 years have witnessed both a lack of awareness of the importance of rational use of antimicrobial agents, and antibiotics in particular, and a stagnation in drug development in the field of antimicrobial medicines and that this is linked to scientific, regulatory and economic challenges;
Amendment 199 #
Motion for a resolution
Paragraph 19
Paragraph 19
19. Welcomes and encourages further research for new antimicrobial drugs, in particular antibiotics with activity against prevalent multidrug-resistant Gram- negative bacteria such as K. pneumoniae and Acinetobacter, as well as for alternative methods aimed at fighting HAIs without using antibiotics and multi-drug resistant tuberculosis (MDR-TB);
Amendment 212 #
Motion for a resolution
Paragraph 20
Paragraph 20
20. Considers it of paramount importance that the Commission should ensure the continuation of the EU Action Plan on Antimicrobial Resistance post-2017, with an emphasis on how to overcome the scientific, regulatory and economic challenges associated with antimicrobial resistance, while including the prevention and control of healthcare-associated infections;
Amendment 225 #
Motion for a resolution
Paragraph 21 a (new)
Paragraph 21 a (new)
21a. Calls on the Commission and Member States to use "adaptive pathways" schemes and other regulatory tools for an earlier patient access to innovative antibacterials to treat resistant infections;
Amendment 229 #
Motion for a resolution
Paragraph 21 b (new)
Paragraph 21 b (new)
21b. Calls on the Member States and the Commission to start a reflection process to develop a new economic model, that de- links the volume of sales from the reward paid for a new antibiotic, for example through a single or a series of fixed payments to the company, which would reflect the societal value of a new antibiotic and allow for sufficient return on investment for the company, while the purchaser would gain the right to use the product and have full control over volumes;
Amendment 230 #
Motion for a resolution
Paragraph 21 c (new)
Paragraph 21 c (new)
21c. Calls on the Commission to engage in the work of the WHO to develop a new economic model, in order to take into consideration the public health concerns and needs;
Amendment 232 #
Motion for a resolution
Paragraph 22 – point a
Paragraph 22 – point a
a) regulate the prescription of antibioticsstrictly implement laws prohibiting the provision of antibiotics without prescription for treatment or prophylaxis so that an appropriate use of medicines is ensured, specifying the therapeutic objective and selecting the appropriate drug therapy; and encourage pharmaceutical companies to pursue proportionate promotional activities, for example by avoiding giving sales representatives prescription targets or by restricting direct payments made to healthcare professionals to discuss these products ;
Amendment 247 #
Motion for a resolution
Paragraph 22 – point c
Paragraph 22 – point c
c) ensuredevelop strategies to support patients’' adherence to and compliance with antibiotictibiotic and other appropriate treatments as prescribed by medical professionals;
Amendment 255 #
Motion for a resolution
Paragraph 22 – point e a (new)
Paragraph 22 – point e a (new)
ea) develop a multi-stakeholder strategy on MDR-TB to encompass key aspects such as prevention, awareness raising, diagnosis, appropriate treatment and adherence and compliance to prescribed medication;
Amendment 265 #
Motion for a resolution
Paragraph 22 – point f a (new)
Paragraph 22 – point f a (new)
fa) increase public funding and new academic positions to focus on exploring and validating new approaches for treating bacterial infections;
Amendment 321 #
Motion for a resolution
Paragraph 26 a (new)
Paragraph 26 a (new)
26a. Urges Member States to involve actively patients' organisations and representatives in the development of policies and programmes on patient safety at all appropriate levels, and to provide them with appropriate support to carry out patient safety activities;
Amendment 325 #
Motion for a resolution
Paragraph 26 b (new)
Paragraph 26 b (new)
26b. Encourages Member States to cooperate on defining minimum patient safety standards and indicators for safety and quality of healthcare EU wide, in consultation with all relevant stakeholders including patient organisations;
Amendment 327 #
Motion for a resolution
Paragraph 27 a (new)
Paragraph 27 a (new)
27a. Encourages further pursuing private-public collaborations, such as the Innovative Medicine Initiative (IMI) programmes "New Drugs for Bad Bugs", COMBACTE, TRANSLOCATION, Drive AB or ENABLE, to harness the power of collaboration;
Amendment 329 #
Motion for a resolution
Paragraph 28 a (new)
Paragraph 28 a (new)
28a. Encourages the European Union to join the global innovation fund, that has been proposed by the 'Antibiotic Resistance Review' conducted in the UK, with the aim to support blue sky science;
Amendment 332 #
Motion for a resolution
Paragraph 28 b (new)
Paragraph 28 b (new)
28b. Calls on the European Commission and the Member States to build on the introduction of the Common Logo for online pharmacies (Implementing Regulation No 699/2014) and to initiate awareness-raising campaigns about the purpose of the Common Logo; whereas that by July 2015 the provisions on the Common Logo have to be applied and all online pharmacies or retailers legally operating in the EU should display it;